 MENLO PARK, Calif., Oct. 13, 2021 GLOBE NEWSWIRE -- CohBar, Inc. NASDAQ: CWBR, a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that data from its CB4211 Phase 1a1b clinical study have been selected for presentation during the late-breaking poster session at The American Association for the Study of Liver Diseases AASLD Annual Meeting The Liver Meeting 2021. This event will be held virtually on November 12 15, 2021. 